The predicting value of post neoadjuvant treatment magnetic resonance imaging: a meta-analysis.
MRI
Neoadjuvant
Rectal cancer
Restaging
Watch and wait
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
06
05
2024
accepted:
13
07
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
aheadofprint
Résumé
Neoadjuvant therapy has become standard of care for locally advanced rectal cancer patients. It is correlated with improved clinical and pathological outcomes, including significant tumor downstaging and organ preservation in certain patients. Magnetic resonance imaging (MRI), which has become the standard for pre-operative staging, is also used for clinical and pre-operative restaging following pre-operative treatment. In this meta-analysis, we aimed to evaluate the concordance between restaging MRI (following the completion of neoadjuvant therapy) and postoperative pathology result. We conducted a meta-analysis following the PRISMA 2020 guidelines. Two independent reviewers searched PubMed and Google Scholar for studies reporting restaging MRI results compared to pathological outcomes. Outcomes included tumor and nodal staging, circumferential resection margin (CRM) and pathological complete response (pCR). Out of 25,000 studies found on the initial search; 33 studies were included. The studies were published between 2005 and 2023 and included 4100 patients (57.14% males). The median age was 62.45 years. The median interval between the conclusion of neoadjuvant treatment and the subsequent restaging MRI was 6 weeks (range 4.14-8.8 weeks). The pooled concordance rates between the restaging MRI and the pathological outcomes for ypT stage and ypN stage were 63.9% (54.5%-73.3%, I Our findings suggest that the concordance rates between restaging MRI and pathological outcomes in rectal cancer patients following neoadjuvant therapy are limited. Caregivers should take these results into consideration when making clinical decisions about these patients. More data should be gathered about the predictive value of MRI after total neoadjuvant therapy as well as immunotherapy in rectal cancer patients.
Identifiants
pubmed: 39174708
doi: 10.1007/s00464-024-11084-3
pii: 10.1007/s00464-024-11084-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Keller DS, Berho M, Perez RO, Wexner SD, Chand M (2020) The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol 17:414–429
pubmed: 32203400
doi: 10.1038/s41575-020-0275-y
MacFarlane JK, Ryall RDH, Heald RJ (1993) Mesorectal excision for rectal cancer. The Lancet 341:457–460
doi: 10.1016/0140-6736(93)90207-W
Cammà C et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284:1008
pubmed: 10944647
doi: 10.1001/jama.284.8.1008
Petrelli F et al (2020) Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 271:440–448
pubmed: 31318794
doi: 10.1097/SLA.0000000000003471
López-Campos F et al (2020) Watch and wait approach in rectal cancer: current controversies and future directions. World J Gastroenterol 26:4218–4239
pubmed: 32848330
pmcid: 7422545
doi: 10.3748/wjg.v26.i29.4218
Brännström F et al (2015) Multidisciplinary team conferences promote treatment according to guidelines in rectal cancer. Acta Oncol 54:447–453
pubmed: 25291075
doi: 10.3109/0284186X.2014.952387
Harbaugh CM et al (2024) Association of national accreditation program for rectal cancer accreditation with outcomes after rectal cancer surgery. J Am Coll Surg. https://doi.org/10.1097/XCS.0000000000001064
doi: 10.1097/XCS.0000000000001064
pubmed: 38546122
Rahma OE et al (2021) Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol 7:1225
pubmed: 34196693
doi: 10.1001/jamaoncol.2021.1683
Fernandes MC, Gollub MJ, Brown G (2022) The importance of MRI for rectal cancer evaluation. Surg Oncol 43:101739
pubmed: 35339339
doi: 10.1016/j.suronc.2022.101739
Gao PF, Lu N, Liu WMRIVS (2023) FDG-PET for diagnosis of response to neoadjuvant therapy in patients with locally advanced rectal cancer. Front Oncol 13:1031581
pubmed: 36741013
pmcid: 9890074
doi: 10.3389/fonc.2023.1031581
Patel UB et al (2012) MRI after treatment of locally advanced rectal cancer: how to report tumor response—the mercury experience. Am J Roentgenol 199:W486–W495
doi: 10.2214/AJR.11.8210
Herold A et al (2022) Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer. Eur J Nucl Med Mol Imaging 50:205–217
pubmed: 36063201
pmcid: 9668962
doi: 10.1007/s00259-022-05936-0
Gefen R et al (2023) How reliable is restaging MRI after neoadjuvant therapy in rectal cancer? Colorectal Dis 25:1631–1637
pubmed: 37376824
doi: 10.1111/codi.16641
Popița A-R et al (2022) Preoperative MRI accuracy after neoadjuvant chemoradiation for locally advanced rectal cancer. Med Pharm Rep 96:258–268
Aryan M et al (2021) Utility of restaging MRI following neoadjuvant chemoradiotherapy for stage II-III rectal adenocarcinoma. Cureus. https://doi.org/10.7759/cureus.19037
doi: 10.7759/cureus.19037
pubmed: 34858737
pmcid: 8612598
Lu Q-Y et al (2022) Contrast-enhanced MRI for T restaging of locally advanced rectal cancer following neoadjuvant chemotherapy and radiation therapy. Radiology 305:364–372
pubmed: 35852424
doi: 10.1148/radiol.212905
Deidda S et al (2023) Limits of clinical restaging in detecting responders after neoadjuvant therapies for rectal cancer. Dis Colon Rectum 66:957–964
pubmed: 36538694
doi: 10.1097/DCR.0000000000002450
Chen C-C, Lee R-C, Lin J-K, Wang L-W, Yang S-H (2005) How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis Colon Rectum 48:722–728
pubmed: 15747073
doi: 10.1007/s10350-004-0851-1
Vojtíšek R, Korčáková E, Mařan J, Šorejs O, Fínek J (2017) Neoadjuvant chemoradiotherapy of the rectal carcinoma—the correlation between the findings on the restaging multiparametric 3T MRI scanning and the surgical findings. Rep Pract Oncol Radiother 22:265–276
pubmed: 28507455
pmcid: 5422007
doi: 10.1016/j.rpor.2017.02.004
Nahas SC et al (2019) Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer. Abdom Radiol 44:3632–3640
doi: 10.1007/s00261-019-01894-8
Mezzi G et al (2009) Endoscopic ultrasound and magnetic resonance imaging forre-staging rectal cancer after radiotherapy. World J Gastroenterol 15:5563
pubmed: 19938195
pmcid: 2785059
doi: 10.3748/wjg.15.5563
Çelik H et al (2023) Diagnostic performance of magnetic resonance imaging in preoperative local staging of rectal cancer after neoadjuvant chemoradiotherapy. Diagn Interv Radiol 29:219–227
pubmed: 36971272
pmcid: 10679710
doi: 10.4274/dir.2022.221333
Laohawiriyakamol S et al (2021) Accuracy of high-resolution rectal magnetic resonance imaging re-staging with histopathology in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Asian J Surg 44:275–279
pubmed: 32712044
doi: 10.1016/j.asjsur.2020.07.001
Aker M et al (2018) Diagnostic accuracy of MRI in assessing tumor regression and identifying complete response in patients with locally advanced rectal cancer after neoadjuvant treatment. Abdom Radiol 43:3213–3219
doi: 10.1007/s00261-018-1627-8
Pomerri F et al (2011) Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery 149:56–64
pubmed: 20452636
doi: 10.1016/j.surg.2010.03.025
Schneider DA et al (2016) Relative value of restaging MRI, CT, and FDG-PET scan after preoperative chemoradiation for rectal cancer. Dis Colon Rectum 59:179–186
pubmed: 26855391
doi: 10.1097/DCR.0000000000000557
Xia Y et al (2024) Computed diffusion-weighted images of rectal cancer: image quality, restaging, and treatment response after neoadjuvant therapy. J Magn Reson Imaging 59:297–308
pubmed: 37165908
doi: 10.1002/jmri.28766
Cho YB et al (2009) Accuracy of MRI and
pubmed: 19823904
doi: 10.1007/s00268-009-0248-3
Kye B-H, Kim H-J, Kim G, Kim J-G, Cho H-M (2016) Multimodal assessments are needed for restaging after neoadjunvant chemoradiation therapy in rectal cancer patients. Cancer Res Treat 48:561–566
pubmed: 26323642
doi: 10.4143/crt.2015.114
Adrian Cot E et al (2018) The accuracy of endorectal ultrasonography and high-resolution magnetic resonance imaging for restaging rectal cancer after neoadjuvant chemoradiotherapy. Ann Ital Chir 89:168–176
Nahas CS, Nahas SC, Bustamante-Lopez LE, Sparapan CM, Ortega CI, Azambuja R, Ribeiro Jr UL, Cotti GC, Imperiale AR, Cecconello IV (2019) T≤ 2N0 TRG1-2 in post-chemoradiation therapy MRI: what can it predict? Surg Technol Int 35:161–168
Zhang Z et al (2023) MRI for nodal restaging after neoadjuvant therapy in rectal cancer with histopathologic comparison. Cancer Imaging 23:67
pubmed: 37443085
pmcid: 10339540
doi: 10.1186/s40644-023-00589-0
Pangarkar S et al (2021) Accuracy of MRI for nodal restaging in rectal cancer: a retrospective study of 166 cases. Abdom Radiol 46:498–505
doi: 10.1007/s00261-020-02708-y
Huh JW, Kwon SY, Lee JH, Kim HR (2015) Comparison of restaging accuracy of repeat FDG-PET/CT with pelvic MRI after preoperative chemoradiation in patients with rectal cancer. J Cancer Res Clin Oncol 141:353–359
pubmed: 25181962
doi: 10.1007/s00432-014-1815-z
Zhan S, Wang X, Huang X, Zhu H (2015) Magnetic resonance imaging in restaging rectal cancer after neoadjuvant chemoradiotherapy. JBUON 20:62–67
pubmed: 25778298
Yu L et al (2019) Accuracy of magnetic resonance imaging in staging rectal cancer with multidisciplinary team: a single-center experience. J Cancer 10:6594–6598
pubmed: 31777588
pmcid: 6856893
doi: 10.7150/jca.32685
Yuval JB et al (2022) MRI at restaging after neoadjuvant therapy for rectal cancer overestimates circumferential resection margin proximity as determined by comparison with whole-mount pathology. Dis Colon Rectum 65:489–496
pubmed: 34803147
pmcid: 8916980
doi: 10.1097/DCR.0000000000002145
Park MJ, Kim SH, Lee SJ, Jang KM, Rhim H (2011) Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy. Radiology 260:771–780
pubmed: 21846762
doi: 10.1148/radiol.11102135
Temmink SJD, Martling A, Angenete E, Nilsson PJ (2023) Complete response rates in rectal cancer: temporal changes over a decade in a population-based nationwide cohort. Eur J Surg Oncol 49:106991
pubmed: 37495447
doi: 10.1016/j.ejso.2023.106991
Bregendahl S et al (2022) Training of radiology specialists in local staging of primary rectal cancer on MRI: a prospective intervention study exploring the impact of various educational elements on the interpretive performance. BMJ Open Qual 11:e001716
pubmed: 35944932
pmcid: 9367186
doi: 10.1136/bmjoq-2021-001716
Brown PJ et al (2019) Radiologist and multidisciplinary team clinician opinions on the quality of MRI rectal cancer staging reports: how are we doing? Clin Radiol 74:637–642
pubmed: 31084973
doi: 10.1016/j.crad.2019.04.015
Wei M-Z, Zhao Z-H, Wang J-Y (2020) The diagnostic accuracy of magnetic resonance imaging in restaging of rectal cancer after preoperative chemoradiotherapy: a meta-analysis and systematic review. J Comput Assist Tomogr 44:102–110
pubmed: 31939890
doi: 10.1097/RCT.0000000000000964
Memon S, Lynch AC, Bressel M, Wise AG, Heriot AG (2015) Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Dis 17:748–761
pubmed: 25891148
doi: 10.1111/codi.12976
Di Costanzo G et al (2023) Artificial intelligence and radiomics in magnetic resonance imaging of rectal cancer a review. Explor Target Anti-Tumor Ther. https://doi.org/10.37349/etat.2023.00142
doi: 10.37349/etat.2023.00142
Trojan J et al (2021) Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H/dMMR rectal cancer. Oncologist 26:e2110–e2114
pubmed: 34431576
pmcid: 8649008
doi: 10.1002/onco.13955